Table 5.
Vinflunine for metastatic/recurrent TTCU: the phase III trial compared to real-life.
| References | Country | n | Vinflunine line | RR | DCR | mPFS | mOS |
|---|---|---|---|---|---|---|---|
| Medioni et al., ECCO, 2013 | France | 134 | II | 22 | 51 | 4.2 | 8.2 |
| Castellano et al., BMC, 2014 | Spain | 102 | II | 24.5 | 65.7 | 3.9 | 10 |
| Palacka et al., Klin Onkol, 2014 | Slovak Republic | 16 | II | 13.3 | – | 2.3 | 5.2 |
| Hegele et al., Urol Int, 2014 | Germany | 21 | II | 19.1 | 47.7 | 4.4 | 6.2 |
| Hussain et al., ASCO GU, 2015 | UK | 37 | II | 32 | 52.6 | – | 9.5 |
| Moriceau et al., Clin Genit, 2015 | France | 19 | II (47%) III or more (53%) | 32 | 53 | 2.9 | 5.6 |
| Retz et al., BMC, 2015 | Germany | 77 | II (66%) I (12%) III or more (22%) | 23.4 | 53.2 | – | 7.7 |
| Bellmunt et al., JCO, 2009 | Europe | 253 | II | 8.6 | 41 | 3 | 6.9 |
| Facchini et al. | Italy | 43 | II (81%) III or more (19%) | 12 | 29 | 2.2 | 6.9 |